On Monday, Ovid Therapeutics Inc (NASDAQ: OVID) was -5.39% drop from the session before settling in for the closing price of $1.67. A 52-week range for OVID has been $0.24 – $2.01.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 24.72%. When this article was written, the company’s average yearly earnings per share was at -23.65%. With a float of $59.52 million, this company’s outstanding shares have now reached $71.11 million.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ovid Therapeutics Inc stocks. The insider ownership of Ovid Therapeutics Inc is 16.29%, while institutional ownership is 35.26%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.2 earnings per share (EPS) during the time that was better than consensus figure (set at -0.23) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -23.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.00% during the next five years compared to 24.72% growth over the previous five years of trading.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
You can see what Ovid Therapeutics Inc (OVID) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.41 in one year’s time.
